Locoregional IL-13Rα2-targeted CAR T cell therapy, including intratumoral and intraventricular injections, has shown promise for high-grade gliomas, suggesting that locoregional delivery may mitigate the need for lymphodepletion [170]. The gene discussed is IL13RA2; the disease is glioma.